The systemic and renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

The purpose of the present study was to investigate the effects of Ang II receptor blockade on the systemic and renal response to acute treat ment with Ng-monomethyl-L-arginine (L-NMMA) in healthy subjects.

Who Took Part

The age groups tagged for this paper are adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the participants and researchers unaware of who received Angiotensin II.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

Renal haemodynamics were measured during water diuresis using renal clearances of [125I]hippuran and [51Cr]EDTA.

Plasma hormones were measured by radioimmunoassays.

What Was Measured

PubMed files the paper under topics including Angiotensin II, Angiotensin Receptor Antagonists, Atrial Natriuretic Factor, Enzyme Inhibitors, Lithium, Nitric Oxide and Sodium.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1999 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the Angiotensin II compound page, all human trials.